Domain Partners — 2015 Investments
1 investments dated 2015 · listed companies and verified rows first · show all
aTyr is a clinical-stage biotechnology company developing therapies derived from tRNA synthetase biology to treat fibrosis and inflammation, with its lead candidate efzofitimod in clinical trials for interstitial lung disease.
BiotechHealthtechMedical DevicesSan Diego, US
Amir Nashat(Non-Management Director)Paul Schimmel(Non-Management Director)Akkaraju Srinivas(Non-Management Director)John D. Mendlein(Executive Officer, Director)David Weiner(Executive Officer)Ed Penhoet(Non-Management Director)
Board seatJames C. Blair· per SEC Form D · $76.3M raise · filed Apr 2015
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.